What is LUCA Science?
Based in Tokyo, Japan, LUCA Science is a pre-clinical stage biopharmaceutical firm dedicated to advancing therapies targeting mitochondrial dysfunction. The company's focus on this critical cellular component positions it within a rapidly evolving field of medicine, aiming to address a range of complex diseases. LUCA Science's strategic approach involves leveraging cutting-edge research to develop novel treatments for conditions with significant unmet medical needs.
How much funding has LUCA Science raised?
LUCA Science has raised a total of $40.1M across 2 funding rounds:
Series A
$9.8M
Series B
$30.3M
Series A (2020): $9.8M with participation from Axil Capital Advisors KK/ Axil Capital Partners
Series B (2022): $30.3M led by Nissay Capital, Fast Track, DCI WALBRIDGE PARTNERS, QB Capital/NCB Venture Capital, Asahi Kasei Pharma America (AKP America), SMBC Venture Capital, and 4BIO Capital
Key Investors in LUCA Science
Nissay Capital
Nissay Capital is a Japan-based organization that provides diverse fundraising solutions and strategic financial advisory services, with a global presence and a focus on driving impactful outcomes for its clients.
DCI WALBRIDGE PARTNERS
DCI WALBRIDGE PARTNERS is a joint venture investing in manufacturing, construction, engineering, real estate, and agriculture, with a particular focus on automotive components and related industries.
Asahi Kasei Pharma America (AKP America)
Asahi Kasei Pharma America is a biopharmaceutical company, a subsidiary of Asahi Kasei Pharma Corp., dedicated to delivering critical care therapeutics to patients worldwide.
What's next for LUCA Science?
With the recent infusion of $30.3M in a major strategic investment, LUCA Science is poised for accelerated growth and development. This capital injection, part of its $40.1M in total financing, will likely fuel further research, expand its pre-clinical pipeline, and potentially support the progression towards clinical trials. The company's trajectory suggests a strong commitment to innovation in mitochondria-based therapies, aiming to establish a significant presence in the biopharmaceutical landscape.
See full LUCA Science company page
